This is a routine director-level Form 144 — not alarming by size or role. However, GLUE has seen 4 insider sales in 30 days (this filing plus 3 prior) totaling ~$732K. That's non-trivial accumulation of selling at a ~$2B cap biotech. Monitor upcoming 10-Q for any pipeline or cash disclosure that might explain the clustering. No immediate trade signal.
Price Chart
Executive Summary
Director Anthony M. Manning filed a Form 144 signaling intent to sell 10,000 shares (~$231K at filing) of Monte Rosa Therapeutics. The shares were acquired via stock option exercise, and the sale is planned as a cash transaction through Morgan Stanley. This is a modest, routine insider sale by a non-CEO director and does not indicate material shift in insider sentiment.
Key Facts
- Director Anthony M. Manning filed Form 144 to sell 10,000 shares of Monte Rosa Therapeutics (GLUE)
- Estimated aggregate sale value ~$231,100 based on filing date pricing
- Shares acquired via stock option exercise on June 29, 2026 (same day as filing)
- Sale planned as cash transaction through Morgan Stanley Smith Barney LLC
- Manning's address is listed as c/o Palatin Technologies — he may be a director at both companies
- Recent 30-day insider activity on GLUE: 3 sells totaling $501K, this filing adds to that pattern
Financial Impact
~$231K proposed sale by one director — roughly 0.012% of Monte Rosa's $2.0B market cap
Risk Factors
- Insider selling cluster over 30 days — 4 separate filings totaling ~$732K — could indicate perception of near-term peak or concern not yet public
- Director's c/o address at Palatin Technologies raises cross-company governance attention, but no conflict evident here
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006574 |
| Document: 0001950047-26-006574-index.html | 0001950047-26-006574 |
| Document: 0001950047-26-006574.txt | 0001950047-26-006574 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $11.26 | awaiting T+60 | — | $10.60 (−5.91%) |
Sep 30, 2026 26d ago | Press Release | $11.26 | awaiting T+60 | — | $10.60 (−5.91%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.60 (−32.56%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.60 (−54.88%) |
Jul 7, 2026 15w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.60 (−55.96%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.60 (−56.24%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.60 (−56.24%) |
Jun 29, 2026 17w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.60 (−56.22%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.60 (−52.47%) |
Jun 2, 2026 20w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.60 (−39.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers